Spots Global Cancer Trial Database for Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
Official Title: A Multi-Center, Open-Label, Phase Ib/II Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Sufatinib in Treating Advanced Neuroendocrine Tumors
Study ID: NCT02267967
Conditions
Interventions
Study Description
Brief Summary: a multicenter, open-label phase Ib study to determine the safety, tolerability and preliminary efficacy of Sulfatinib 300 mg once a day in treating advanced neuroendocrine tumors
Detailed Description: The study population is patients with low- or intermediate-grade (G1 or G2) advanced NET who have failed in standard treatment or are unable to receive standard treatment.Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle. Investigators will evaluate the clinical tumor response to Sulfatinib, and if investigators determine that the patient can benefit from the continuation of treatment, the patient will continue the Sulfatinib treatment. The duration of study will be 2 years. At the time of study completion, if investigators believe patients can continue to benefit from the investigational product, patients may be provided with Sulfatinib with the agreement of the sponsor.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Peking Union Medical College Hospital, Beijing, Beijing, China
the 307 Hospital of People's Liberation Army, Beijing, Beijing, China
Beijing Cancer Hospital, Beijing, Beijing, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China
The first affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China
Contact Details
Name: Jing Li, MD
Affiliation: Hutchison Medi Pharma
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
